2004
DOI: 10.1055/s-2004-821075 View full text |Buy / Rent full text
|
|

Abstract: Surgery combined with chemotherapy is a therapeutic option in selected patients with SCLC. Pathologic nodal status and response to induction chemotherapy are predictors of survival.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
5
0
12
0
1

Year Published

2009
2009
2014
2014

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

0
12
0
1
Order By: Relevance
“…One Japanese multi-institutional phase II study (JCOG9101) has reported that recurrence after surgery occurred in 43% (26/61) of patients overall, in 29% (10/35) of patients with p-stage I disease, in 50% (4/8) of patients with p-stage II, and in 67% (12/18) of patients with p-stage III, and that the incidence of brain metastasis was 15% (9/61) in patients overall, 11% (4/35) in patients with p-stage I disease, 38% (3/8) in patients with p-stage II, and 11% (2/18) in patients with p-stage III [20]. Another Japanese study showed that relapse after surgery occurred in 34 of 69 (49%) patients who underwent complete resection of SCLC and in 27% (8/30) of patients with p-stage I disease, 58% (7/12) of patients with p-stage II, 69% (18/26) of patients with p-stage III, and 100% (1/1) of patients with p-stage IV [19].…”
Section: Discussionmentioning
See 1 more Smart Citation
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 14 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…One Japanese multi-institutional phase II study (JCOG9101) has reported that recurrence after surgery occurred in 43% (26/61) of patients overall, in 29% (10/35) of patients with p-stage I disease, in 50% (4/8) of patients with p-stage II, and in 67% (12/18) of patients with p-stage III, and that the incidence of brain metastasis was 15% (9/61) in patients overall, 11% (4/35) in patients with p-stage I disease, 38% (3/8) in patients with p-stage II, and 11% (2/18) in patients with p-stage III [20]. Another Japanese study showed that relapse after surgery occurred in 34 of 69 (49%) patients who underwent complete resection of SCLC and in 27% (8/30) of patients with p-stage I disease, 58% (7/12) of patients with p-stage II, 69% (18/26) of patients with p-stage III, and 100% (1/1) of patients with p-stage IV [19].…”
Section: Discussionmentioning
“…However, use of PCI after combined-modality treatment with surgery for resectable LS-SCLC has not yet been investigated sufficiently. As far as we are aware, only 2 Japanese studies have reported the frequency of brain relapse after surgery for LS-SCLC [19,20]. One Japanese multi-institutional phase II study (JCOG9101) has reported that recurrence after surgery occurred in 43% (26/61) of patients overall, in 29% (10/35) of patients with p-stage I disease, in 50% (4/8) of patients with p-stage II, and in 67% (12/18) of patients with p-stage III, and that the incidence of brain metastasis was 15% (9/61) in patients overall, 11% (4/35) in patients with p-stage I disease, 38% (3/8) in patients with p-stage II, and 11% (2/18) in patients with p-stage III [20].…”
Section: Discussionmentioning
“…The importance of response to chemotherapy on outcome in patients has been demonstrated in the setting of multiple tumors, including rectal, lung, and esophageal, and more recently, with colorectal cancer metastatic to the liver [19][20][21]. In a study by Adam et al the response to chemotherapy was evaluated through imaging studies of abdominopelvic and chest CT scan and abdominopelvic ultrasound utilizing the World Health Organization criteria (WHO) [22].…”
Section: Discussionmentioning
“…One Japanese multi-institutional phase II study (JCOG9101) has reported that the overall incidence of BM was 15% (9/61) in patients with surgically resected SCLC, but only 11% (4/35) in patients with p-stage I disease compared to 19.2% in patients with p-stage II or stage III disease [ 15 ]. Nakamura et al analyzed the frequency of BM as a first relapse site and found a 7% (2/30) BM rate for patients with p-stage I disease, 25% (3/12) for patients with p-stage II SCLC, and 27% (7/26) for patients with p-stage III [ 21 ]. Ogawa et al also reported the frequency of BM, but only 28 patients were included in the study [ 22 ].…”
Section: Discussionmentioning